Loading
Adding the anti-GD2 antibody to relapse chemotherapy doubled response rates in relapsed neuroblastoma, and the idea is now moving into first-line induction.
Adding the anti-GD2 antibody dinutuximab to irinotecan and temozolomide chemotherapy is a combination pairing for relapsed neuroblastoma that has become the standard treatment at first relapse. Chemotherapy releases antigen and depletes suppressive cells while the antibody directs antibody-dependent cellular cytotoxicity against GD2, a disialoganglioside that chemotherapy does not downregulate. In the randomised phase 2 ANBL1221 trial the irinotecan-temozolomide-dinutuximab arm produced far more responses than the temsirolimus comparator, and a confirmatory expansion supported the result. The concept is now moving into first-line induction in ANBL17P1, which tests dinutuximab during induction, and naxitamab combined with chemotherapy shows a similar pattern.
Shares Naxitamab, GD2 (disialoganglioside), High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Temozolomide, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Temozolomide, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares Naxitamab, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).